Hologic (NASDAQ:HOLX) announced its earnings results on Wednesday. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.38 by $0.37, MarketWatch Earnings reports. The company had revenue of $822.90 million during the quarter, compared to analysts’ expectations of $622.96 million. Hologic had a net margin of 20.03% and a return on equity of 31.77%. Hologic’s quarterly revenue was down 3.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.63 earnings per share. Hologic updated its Q4 2020
After-Hours guidance to 0.95-1.15 EPS and its Q4 guidance to $0.95-$1.15 EPS.

HOLX traded down $0.58 during trading on Friday, reaching $69.13. 53,200 shares of the company’s stock were exchanged, compared to its average volume of 1,892,233. The company has a current ratio of 1.31, a quick ratio of 1.04 and a debt-to-equity ratio of 1.32. Hologic has a one year low of $26.49 and a one year high of $70.15. The firm has a fifty day moving average price of $57.08 and a two-hundred day moving average price of $49.97. The stock has a market capitalization of $17.97 billion, a PE ratio of 28.11, a price-to-earnings-growth ratio of 3.38 and a beta of 1.47.

In other news, insider Peter J. Valenti III sold 10,493 shares of Hologic stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $54.07, for a total transaction of $567,356.51. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Sally Crawford sold 31,950 shares of Hologic stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $51.99, for a total transaction of $1,661,080.50. Following the transaction, the director now owns 126,847 shares in the company, valued at approximately $6,594,775.53. The disclosure for this sale can be found here. Insiders have sold 243,932 shares of company stock valued at $12,507,250 in the last ninety days. Insiders own 1.00% of the company’s stock.

A number of research analysts recently commented on the company. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Monday. Cowen raised Hologic from a “market perform” rating to an “outperform” rating and set a $64.00 price target for the company in a research note on Tuesday, June 30th. Zacks Investment Research downgraded Hologic from a “hold” rating to a “sell” rating and set a $52.00 price target for the company. in a research note on Tuesday, April 28th. JPMorgan Chase & Co. boosted their price target on Hologic from $45.00 to $55.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Finally, Wells Fargo & Co boosted their price target on Hologic from $63.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Hologic currently has an average rating of “Buy” and an average target price of $64.28.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Article: What is a blue-chip stock?

Earnings History for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.